Does the media favor AUPH or PCVX?

In the previous week, Vaxcyte had 17 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 20 mentions for Vaxcyte and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.08 beat Vaxcyte's score of 0.36 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 4 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUPH or APGE?

In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Apogee Therapeutics. MarketBeat recorded 3 mentions for Aurinia Pharmaceuticals and 1 mentions for Apogee Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.08 beat Apogee Therapeutics' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TGTX or AUPH?

In the previous week, TG Therapeutics had 6 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 9 mentions for TG Therapeutics and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.08 beat TG Therapeutics' score of 0.65 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PRAX or AUPH?

In the previous week, Praxis Precision Medicines and Praxis Precision Medicines both had 3 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 1.08 beat Praxis Precision Medicines' score of 0.57 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AUPH or SYRE?

In the previous week, Spyre Therapeutics had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 4 mentions for Spyre Therapeutics and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.08 beat Spyre Therapeutics' score of 0.38 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aurinia Pharmaceuticals (AUPH) Competitors

$16.64 +0.28 (+1.72%)

As of 12:28 PM Eastern

Compare

AUPH vs. PCVX, APGE, TGTX, PRAX, and SYRE

Should you buy Aurinia Pharmaceuticals stock or one of its competitors? Aurinia Pharmaceuticals's main competitors and comparable companies include Vaxcyte (PCVX), Apogee Therapeutics (APGE), TG Therapeutics (TGTX), Praxis Precision Medicines (PRAX), and Spyre Therapeutics (SYRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Aurinia Pharmaceuticals presently has a consensus target price of $17.67, indicating a potential upside of 7.99%. Vaxcyte has a consensus target price of $110.50, indicating a potential upside of 65.42%. Given Vaxcyte's higher probable upside, analysts clearly believe Vaxcyte is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

In the previous week, Vaxcyte had 17 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 20 mentions for Vaxcyte and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.08 beat Vaxcyte's score of 0.36 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	4 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Vaxcyte's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Vaxcyte	N/A	-37.56%	-33.62%

Aurinia Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.69	$287.20M	$2.29	7.14
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Summary

Aurinia Pharmaceuticals beats Vaxcyte on 10 of the 14 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Aurinia Pharmaceuticals presently has a consensus price target of $17.67, suggesting a potential upside of 7.99%. Apogee Therapeutics has a consensus price target of $126.77, suggesting a potential downside of 6.14%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Apogee Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Apogee Therapeutics	N/A	-29.88%	-28.08%

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aurinia Pharmaceuticals has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.69	$287.20M	$2.29	7.14
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Apogee Therapeutics. MarketBeat recorded 3 mentions for Aurinia Pharmaceuticals and 1 mentions for Apogee Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.08 beat Apogee Therapeutics' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Summary

Aurinia Pharmaceuticals beats Apogee Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

In the previous week, TG Therapeutics had 6 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 9 mentions for TG Therapeutics and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.08 beat TG Therapeutics' score of 0.65 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has a net margin of 100.84% compared to TG Therapeutics' net margin of 55.22%. TG Therapeutics' return on equity of 73.49% beat Aurinia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

TG Therapeutics presently has a consensus target price of $63.00, suggesting a potential upside of 15.94%. Aurinia Pharmaceuticals has a consensus target price of $17.67, suggesting a potential upside of 7.99%. Given TG Therapeutics' higher possible upside, equities research analysts clearly believe TG Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

TG Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.50	$447.18M	$2.74	19.83
Aurinia Pharmaceuticals	$283.05M	7.69	$287.20M	$2.29	7.14

Summary

TG Therapeutics beats Aurinia Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Aurinia Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	794.63	-$303.27M	-$12.93	N/A
Aurinia Pharmaceuticals	$283.05M	7.69	$287.20M	$2.29	7.14

Praxis Precision Medicines has a beta of 2.79, indicating that its share price is 179% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

Praxis Precision Medicines presently has a consensus target price of $613.26, suggesting a potential upside of 152.02%. Aurinia Pharmaceuticals has a consensus target price of $17.67, suggesting a potential upside of 7.99%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, research analysts clearly believe Praxis Precision Medicines is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Praxis Precision Medicines' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

In the previous week, Praxis Precision Medicines and Praxis Precision Medicines both had 3 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 1.08 beat Praxis Precision Medicines' score of 0.57 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aurinia Pharmaceuticals beats Praxis Precision Medicines on 9 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Spyre Therapeutics?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Aurinia Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.69	$287.20M	$2.29	7.14
Spyre Therapeutics	$890K	9,211.98	-$155.20M	-$1.95	N/A

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.1, suggesting that its share price is 210% more volatile than the broader market.

Aurinia Pharmaceuticals presently has a consensus price target of $17.67, suggesting a potential upside of 7.99%. Spyre Therapeutics has a consensus price target of $110.40, suggesting a potential upside of 37.23%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spyre Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Spyre Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Spyre Therapeutics	N/A	-30.74%	-22.23%

In the previous week, Spyre Therapeutics had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 4 mentions for Spyre Therapeutics and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.08 beat Spyre Therapeutics' score of 0.38 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aurinia Pharmaceuticals and Spyre Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Aurinia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUPH vs. The Competition

Export

Metric	Aurinia Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.21B	$3.89B	$7.28B	$13.01B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	7.27	12.99	275.44	25.42
Price / Sales	7.82	1,141.69	559.80	78.81
Price / Cash	16.33	118.50	77.16	53.04
Price / Book	3.77	16.88	10.66	5.96
Net Income	$287.20M	-$22.65M	$3.50B	$380.62M
7 Day Performance	3.94%	-5.64%	-3.65%	-3.75%
1 Month Performance	1.41%	-13.53%	-8.06%	-6.62%
1 Year Performance	48.18%	6.87%	2.58%	-4.38%

Aurinia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUPH Aurinia Pharmaceuticals	3.554 of 5 stars	$16.64 +1.7%	$17.67 +6.2%	+47.4%	$2.21B	$283.05M	7.27	128
PCVX Vaxcyte	2.8185 of 5 stars	$73.82 +30.7%	$108.60 +47.1%	+52.5%	$8.40B	N/A	N/A	507	Analyst Forecast High Trading Volume
APGE Apogee Therapeutics	0.794 of 5 stars	$135.07 flat	$126.77 -6.1%	N/A	$8.40B	N/A	N/A	91	News Coverage
TGTX TG Therapeutics	3.5529 of 5 stars	$53.91 -0.7%	$63.00 +16.9%	+58.8%	$8.31B	$799.54M	19.68	399
PRAX Praxis Precision Medicines	2.6439 of 5 stars	$283.56 -4.0%	$612.42 +116.0%	+364.9%	$8.25B	$8.55M	N/A	168	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUPH) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. PCVX, APGE, TGTX, PRAX, and SYRE

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Summary

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Summary

How does Aurinia Pharmaceuticals compare to TG Therapeutics?

Summary

How does Aurinia Pharmaceuticals compare to Praxis Precision Medicines?

Summary

How does Aurinia Pharmaceuticals compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. PCVX, APGE, TGTX, PRAX, and SYRE

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Do analysts rate AUPH or PCVX?

Do institutionals & insiders hold more shares of AUPH or PCVX?

Which has more volatility & risk, AUPH or PCVX?

Does the media favor AUPH or PCVX?

Is AUPH or PCVX more profitable?

Which has preferable valuation & earnings, AUPH or PCVX?

Summary

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Do analysts rate AUPH or APGE?

Is AUPH or APGE more profitable?

Do institutionals and insiders hold more shares of AUPH or APGE?

Which has stronger earnings and valuation, AUPH or APGE?

Does the media favor AUPH or APGE?

Which has more risk and volatility, AUPH or APGE?

Summary

How does Aurinia Pharmaceuticals compare to TG Therapeutics?

Does the media favor TGTX or AUPH?

Is TGTX or AUPH more profitable?

Do analysts prefer TGTX or AUPH?

Which has more risk & volatility, TGTX or AUPH?

Do insiders and institutionals hold more shares of TGTX or AUPH?

Which has better earnings and valuation, TGTX or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to Praxis Precision Medicines?

Which has better valuation & earnings, PRAX or AUPH?

Which has more volatility & risk, PRAX or AUPH?

Do analysts recommend PRAX or AUPH?

Do insiders and institutionals hold more shares of PRAX or AUPH?

Is PRAX or AUPH more profitable?

Does the media prefer PRAX or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to Spyre Therapeutics?

Which has stronger valuation and earnings, AUPH or SYRE?

Do institutionals and insiders have more ownership in AUPH or SYRE?

Which has more volatility & risk, AUPH or SYRE?

Do analysts rate AUPH or SYRE?

Is AUPH or SYRE more profitable?

Does the media favor AUPH or SYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools